Michael Wiederhorn
Stock Analyst at Oppenheimer
(4.80)
# 503
Out of 4,509 analysts
1155
Total ratings
60.5%
Success rate
12.2%
Average return
Main Sectors:
Stocks Rated by Michael Wiederhorn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PACS PACS Group | Rated: Buy | $42 → $48 | $43.27 | +10.93% | 5 | May 13, 2026 | |
| PNTG The Pennant Group | Maintained: Buy | $40 | $39.86 | +0.35% | 18 | May 8, 2026 | |
| GRDN Guardian Pharmacy Services | Maintained: Buy | $43 | $40.29 | +6.73% | 7 | May 7, 2026 | |
| ADUS Addus HomeCare | Rated: Buy | $155 | $108.86 | +42.38% | 113 | May 6, 2026 | |
| HUM Humana | Maintained: Buy | $250 → $260 | $406.00 | -35.96% | 79 | Apr 30, 2026 | |
| CNC Centene | Rated: Buy | $45 → $58 | $68.29 | -15.07% | 163 | Apr 29, 2026 | |
| HCA HCA Healthcare | Rated: Buy | $520 | $390.74 | +33.08% | 95 | Apr 27, 2026 | |
| CYH Community Health Systems | Maintained: Buy | $4 | $3.48 | +14.94% | 120 | Apr 23, 2026 | |
| UNH UnitedHealth Group | Rated: Buy | $385 → $405 | $429.09 | -5.61% | 87 | Apr 22, 2026 | |
| CHE Chemed | Maintained: Buy | $500 | $492.27 | +1.57% | 117 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $168.39 | - | 86 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $5.92 | - | 12 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 → $7 | $9.65 | -27.46% | 30 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $13.22 | - | 71 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $365 | $304.50 | +19.87% | 74 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $105.90 | n/a | 17 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3 | $0.0001 | n/a | 6 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $44.14 | n/a | 1 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $425.17 | n/a | 48 | Jun 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $7 | $0.000001 | n/a | 6 | Aug 19, 2014 |
PACS Group
May 13, 2026
Rated: Buy
Price Target: $42 → $48
Current: $43.27
Upside: +10.93%
The Pennant Group
May 8, 2026
Maintained: Buy
Price Target: $40
Current: $39.86
Upside: +0.35%
Guardian Pharmacy Services
May 7, 2026
Maintained: Buy
Price Target: $43
Current: $40.29
Upside: +6.73%
Addus HomeCare
May 6, 2026
Rated: Buy
Price Target: $155
Current: $108.86
Upside: +42.38%
Humana
Apr 30, 2026
Maintained: Buy
Price Target: $250 → $260
Current: $406.00
Upside: -35.96%
Centene
Apr 29, 2026
Rated: Buy
Price Target: $45 → $58
Current: $68.29
Upside: -15.07%
HCA Healthcare
Apr 27, 2026
Rated: Buy
Price Target: $520
Current: $390.74
Upside: +33.08%
Community Health Systems
Apr 23, 2026
Maintained: Buy
Price Target: $4
Current: $3.48
Upside: +14.94%
UnitedHealth Group
Apr 22, 2026
Rated: Buy
Price Target: $385 → $405
Current: $429.09
Upside: -5.61%
Chemed
Mar 31, 2026
Maintained: Buy
Price Target: $500
Current: $492.27
Upside: +1.57%
Mar 20, 2026
Maintained: Buy
Price Target: n/a
Current: $168.39
Upside: -
Mar 20, 2026
Maintained: Buy
Price Target: n/a
Current: $5.92
Upside: -
Mar 3, 2026
Maintained: Buy
Price Target: $12 → $7
Current: $9.65
Upside: -27.46%
Nov 19, 2025
Maintained: Hold
Price Target: n/a
Current: $13.22
Upside: -
Oct 31, 2025
Maintained: Buy
Price Target: $365
Current: $304.50
Upside: +19.87%
Aug 9, 2024
Maintained: Hold
Price Target: n/a
Current: $105.90
Upside: n/a
Mar 2, 2023
Maintained: Buy
Price Target: $3
Current: $0.0001
Upside: n/a
Feb 9, 2018
Reiterated: Buy
Price Target: $35
Current: $44.14
Upside: n/a
Jun 7, 2017
Rated: Hold
Price Target: n/a
Current: $425.17
Upside: n/a
Aug 19, 2014
Rated: Buy
Price Target: $7
Current: $0.000001
Upside: n/a